Synaptogenix Stock In The News
| SNPX Stock | USD 2.72 0.18 6.21% |
Our overall analysis of Synaptogenix's news coverage and content from conventional and social sources shows investors' bearish mood towards Synaptogenix. The specific impact of Synaptogenix news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Synaptogenix's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Synaptogenix headlines in addition to utilizing other, more conventional financial analysis modules. Check out Synaptogenix Backtesting and Synaptogenix Hype Analysis. For more information on how to buy Synaptogenix Stock please use our How to Invest in Synaptogenix guide.
Synaptogenix |
Synaptogenix Today Top News and Investor Outlook
Synaptogenix Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Synaptogenix and other traded companies coverage with news coverage. We help investors stay connected with Synaptogenix headlines for the 14th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Synaptogenix Stock performance. Please note that trading solely based on the Synaptogenix hype is not for everyone as timely availability and quick action are needed to avoid losses.
Synaptogenix stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Synaptogenix earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Synaptogenix that are available to investors today. That information is available publicly through Synaptogenix media outlets and privately through word of mouth or via Synaptogenix internal channels. However, regardless of the origin, that massive amount of Synaptogenix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Synaptogenix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Synaptogenix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Synaptogenix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Synaptogenix alpha.
Synaptogenix Largest EPS Surprises
Earnings surprises can significantly impact Synaptogenix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-10 | 2022-09-30 | -0.48 | -0.43 | 0.05 | 10 | ||
2022-08-05 | 2022-06-30 | -0.48 | -0.54 | -0.06 | 12 | ||
2023-03-21 | 2022-12-31 | -0.46 | -0.63 | -0.17 | 36 | ||
2023-05-15 | 2023-03-31 | -0.56 | -0.26 | 0.3 | 53 | ||
2024-02-28 | 2023-12-31 | -0.38 | -0.051 | 0.329 | 86 | ||
2023-11-13 | 2023-09-30 | -0.37 | -0.0338 | 0.3362 | 90 |
Synaptogenix Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Synaptogenix Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
7th of March 2025
Disposition of tradable shares by Alkon Daniel L. of Synaptogenix subject to Rule 16b-3 at Alkon Daniel L.
7th of March 2025
Acquisition by Jeffrey McGroarty of 165199 shares of Annovis Bio at 20.97 subject to Rule ... at MacroaxisInsider
7th of March 2025
Reviva Pharmaceuticals Holdings, Inc. Receives 11.40 Average Price Target from Analysts at thelincolnianonline.com
4th of March 2025
Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment... at news.google.com
27th of February 2025
Acquisition by Shanahan William S of 25140 shares of Cyclo Therapeutics subject to Rule 16... at MacroaxisInsider
25th of February 2025
EXCLUSIVE Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 at finance.yahoo.com
18th of February 2025
Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Inve... at news.google.com
12th of February 2025
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer at finance.yahoo.com
10th of February 2025
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of ... at globenewswire.com
7th of February 2025
Annovis to Present at Oppenheimers 35th Annual Healthcare Life Sciences Conference at globenewswire.com
7th of February 2025
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC Op... at businesswire.com
4th of February 2025
Annovis Bio, Inc. Announces Closing of 21 Million Public Offering at finance.yahoo.com
4th of February 2025
Why INmune Bio Inc Is Skyrocketing So Far In 2025 at insidermonkey.com
3rd of February 2025
Why INmune Bio Inc Is Skyrocketing So Far In 2025 - Yahoo Finance at news.google.com
30th of January 2025
Reviva to Participate in the 2025 BIO CEO Investor Conference at globenewswire.com
15th of January 2025
Acquisition by Alkon Daniel L. of 75000 shares of Synaptogenix subject to Rule 16b-3 at Alkon Daniel L.
6th of January 2025
Cyclo Therapeutics, Inc. announced that it has received 1 million in funding - Marketscree... at news.google.com
23rd of December 2024
Acquisition by Mcgrath Lynne Fahey of 25000 shares of Alzamend Neuro at 1.213 subject to R... at MacroaxisInsider
17th of December 2024
Reviva Announces Pricing of 18.0 Million Public Offering of Common Stock and Warrants at gurufocus.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Synaptogenix in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Synaptogenix's short interest history, or implied volatility extrapolated from Synaptogenix options trading.
Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.